Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
brief summary
This phase II trial tests how well polatuzumab vedotin, mosunetuzumab, and acalabrutinib work in treating patients with mantle cell lymphoma. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug called monomethyl auristatin E. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD79B receptors, and delivers monomethyl auristatin E to kill them. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving polatuzumab vedotin, mosunetuzumab, and acalabrutinib together may be an effective treatment option for patients with mantle cell lymphoma.
detailed description
OUTLINE:
INDUCTION: Patients receive polatuzumab vedotin intravenously (IV) over 30-90 minutes on day 1 of cycles 1-6, mosunetuzumab subcutaneously (SC) on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2-17, and acalabrutinib orally (PO) twice daily (BID) on days 1-21 of cycles 1-17. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve less than partial response (PR) discontinue study. Standard risk patients who achieve CR proceed to surveillance. Responding high-risk patients and responding standard risk patients who fail to achieve CR proceed to maintenance.
MAINTENANCE: Patients receive mosunetuzumab SC on day 1 of each cycle and acalabrutinib PO BID on days 1-56 of each cycle. Cycles repeat every 56 days for up to 12 cycles (cycles 18-29) in the absence of disease progression or unacceptable toxicity.
Patients undergo collection of blood samples, fludeoxyglucose F-18 (FDG) positron emission tomography (PET)/computed tomography (CT), and core biopsy (optional) throughout the trial and undergo bone marrow aspiration (BMA) and bone marrow biopsy (BMB) at screening (optional) and on study.
After completion of study treatment, patients are followed for up to 5 years.
official title
PAcMan: Polatuzumab Vedotin, Acalabrutinib and Mosunetuzumab Response-Adapted Therapy for Previously Untreated Mantle Cell Lymphoma